{"id":"W4416018921","doi":"10.1016/j.ijgc.2025.102743","title":"VIBOSTOLIMAB AND PEMBROLIZUMAB COFORMULATION COMBINED WITH LENVATINIB FOR MISMATCH REPAIR-PROFICIENT ADVANCED ENDOMETRIAL CANCER: RESULTS FROM COHORT B2 OF THE PHASE 2 KEYVIBE-005 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston Health Sciences Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; Endometrial cancer; Cohort; Phases of clinical research; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001769206,0.0008733327,0.0014455,0.000283405,0.0003230359,0.001261759,0.0005640088,0.0007590384,0.002749598],"category_scores_gemma":[0.001924422,0.0005226939,0.002099042,0.0005285494,0.0003889696,0.0008743248,0.0004393275,0.001770591,0.0007003546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008288465,"about_ca_system_score_gemma":0.001035473,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001763911,"about_ca_topic_score_gemma":0.00412285,"domain_scores_codex":[0.999081,0.0004536387,0.00004329778,0.0001698032,0.0001015833,0.0001506386],"domain_scores_gemma":[0.9991933,0.0001661026,0.0002602131,0.0001073707,0.0000646984,0.0002083411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7580734,0.006226516,0.1117551,0.001104065,0.01499233,0.00018007,0.0001935719,0.001550485,0.01205558,0.0003380634,0.0074999,0.08603091],"study_design_scores_gemma":[0.3756305,0.137925,0.4400955,0.0003924997,0.01899495,0.0007075884,0.0005129444,0.001955473,0.004172295,0.0008899813,0.01861043,0.0001128811],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883032,0.006008905,0.0003059333,0.0003816073,0.0001378654,0.00030215,0.002949434,0.00003002145,0.001580917],"genre_scores_gemma":[0.9884803,0.002444823,0.0005282823,0.0006358133,0.0001626213,0.0003878306,0.005861104,0.00002503401,0.00147416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002749598,"threshold_uncertainty_score":0.009356558,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02601424398407073,"score_gpt":0.3690824225653903,"score_spread":0.3430681785813196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}